Opinion
Video
Luspatercept With or Without Ruxolitinib for the Treatment of Anemia in Patients With MF: Data From ACE-536-MF-001
Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, discuss luspatercept with or without ruxolitinib for the treatment of anemia in patients with myelofibrosis. The combination has demonstrated promise in reducing transfusion dependency, as seen in data from ACE-536-MF-001, with ongoing phase 3 trials.
EP: 1.How JAK Inhibitors Have Shaped the Landscape of MF
EP: 2.Pelabresib Plus Ruxolitinib for JAK Inhibitor-Naïve Patients: Data From MANIFEST and MANIFEST-2
EP: 3.Navitoclax Plus Ruxolitinib for Untreated MF: Data From TRANSFORM-1
EP: 4.Navtemadlin Plus Ruxolitinib for Patients With MF who had Suboptimal Responses to Ruxolitinib
EP: 5.Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Patients: Updated Results From XPORT-MF-034
Now Viewing
EP: 6.Luspatercept With or Without Ruxolitinib for the Treatment of Anemia in Patients With MF: Data From ACE-536-MF-001
EP: 7.Future Directions in Combination Therapies for Myelofibrosis
EP: 8.Key Efficacy and Safety Takeaways From Recent Data on JAK Inhibitors for MF
EP: 9.The FREEDOM-2 Trial: Efficacy and Safety of Fedratinib in Patients With MF Previously Treated With Ruxolitinib
EP: 10.Selection and Sequencing of JAK Inhibitors for Patients With MF
EP: 11.Individualizing Therapy Goals for Patients With Myelofibrosis
EP: 12.Emerging Treatments for Myelofibrosis
Related Videos
Related Content
